Luna Innovations win NIH contract to develop ribosomal S6 kinase therapeutics

Luna Innovations has been awarded a $2.1 million three-year contract from the NIH to work on ribosomal S6 kinase (RSK) as a target to prevent infectious disease.

Merck Serono submit EU application for Erbitux in Head and Neck Cancer

Merck Serono have submitted a EU application for Erbitux (cetuximab) to be used as a first line treatment in patients with metastatic squamous cell carcinoma of the head and neck.

Rhabdomyolysis – possible adverse effect of Imatinib

In a letter to the New England Journal of Medicine French doctors have reported a case of severerhabdomyolysis following treatment with Gleevec (imatinib). The patient was taking imatinib as part of a clinical trial for the treatment of aggressive fibromatosis.